Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.36% | -29.24% | 54.85% | -0.05% | 83.90% |
| Total Depreciation and Amortization | -3.15% | -2.31% | -63.38% | 62.10% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.63% | 44.84% | 20.02% | 106.30% | -128.26% |
| Change in Net Operating Assets | -840.96% | -128.60% | -19.16% | -52.91% | -- |
| Cash from Operations | -191.25% | -844.93% | 116.48% | 77.54% | -- |
| Capital Expenditure | -- | -- | -- | 107.82% | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -- | -- | 107.82% | -- |
| Total Debt Issued | -- | -100.00% | -70.00% | -- | -- |
| Total Debt Repaid | 82.63% | -365.83% | -256.41% | 78.92% | -- |
| Issuance of Common Stock | 426.88% | -- | -- | -99.20% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,056.07% | -- | -- | 100.00% | -- |
| Cash from Financing | 492.80% | 5,032.98% | -122.49% | -96.71% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 271,720.00% | -100.91% | 116.34% | 46.00% | -- |